Dr. Kropf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Queens Rd
Ste 600
Charlotte, NC 28204Phone+1 980-302-6600Fax+1 980-302-6605
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2006 - 2009- UPMC Medical EducationResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003
Certifications & Licensure
NC State Medical License 2021 - 2025
PA State Medical License 2003 - 2021- American Board of Internal Medicine Hematology
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS Start of enrollment: 2013 Apr 01
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
- Join now to see all
Publications & Presentations
PubMed
- The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.Jan S Moreb, Lori Lantos, Franklin Chen, Kathleen Elliott, James Dugan
Transfusion and Apheresis Science. 2023-12-01 - 3 citationsGuadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.Pierre Fenaux, Marco Gobbi, Patricia L Kropf, Jean-Pierre J Issa, Gail J Roboz
Blood Advances. 2023-09-12 - 9 citationsSafety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H Duong
Clinical Cancer Research. 2022-12-15
Journal Articles
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Lectures
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patie...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
